var data={"title":"Treatment protocols for pancreatic cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for pancreatic cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-pancreatic-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H8525276\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with pancreatic cancer, both in the adjuvant setting and for advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with pancreatic cancer. Additional regimens may be added over time, particularly as treatment for pancreatic cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with pancreatic cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=chemotherapy-for-advanced-exocrine-pancreatic-cancer\" class=\"medical medical_review\">&quot;Chemotherapy for advanced exocrine pancreatic cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-for-potentially-resectable-exocrine-pancreatic-cancer\" class=\"medical medical_review\">&quot;Treatment for potentially resectable exocrine pancreatic cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-chemotherapy-and-radiation-for-nonmetastatic-locally-advanced-unresectable-and-borderline-resectable-exocrine-pancreatic-cancer\" class=\"medical medical_review\">&quot;Initial chemotherapy and radiation for nonmetastatic, locally advanced, unresectable and borderline resectable, exocrine pancreatic cancer&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H8525441\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H8525449\"><span class=\"h2\">Adjuvant setting</span></p><p class=\"headingAnchor\" id=\"H8525474\"><span class=\"h3\">Adjuvant gemcitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F81436\" class=\"graphic graphic_table graphicRef81436 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H3643984002\"><span class=\"h3\">Adjuvant gemcitabine plus capecitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109104\" class=\"graphic graphic_table graphicRef109104 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H8525513\"><span class=\"h2\">Locally advanced/metastatic disease</span></p><p class=\"headingAnchor\" id=\"H8525538\"><span class=\"h3\">Gemcitabine monotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F60330\" class=\"graphic graphic_table graphicRef60330 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H428485721\"><span class=\"h3\">Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89668\" class=\"graphic graphic_table graphicRef89668 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H3139598706\"><span class=\"h3\">Gemcitabine plus capecitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F103038\" class=\"graphic graphic_table graphicRef103038 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H8525617\"><span class=\"h3\">FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F79571\" class=\"graphic graphic_table graphicRef79571 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H2117393642\"><span class=\"h3\">Modified FOLFIRINOX for metastatic pancreatic cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109546\" class=\"graphic graphic_table graphicRef109546 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H936511973\"><span class=\"h3\">Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50132\" class=\"graphic graphic_table graphicRef50132 \">table 8</a>) </p><p class=\"headingAnchor\" id=\"H2763016320\"><span class=\"h3\">Liposomal irinotecan and 5-FU for metastatic pancreatic cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109026\" class=\"graphic graphic_table graphicRef109026 \">table 9</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85690 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H8525276\" id=\"outline-link-H8525276\">INTRODUCTION</a></li><li><a href=\"#H8525441\" id=\"outline-link-H8525441\">REGIMENS</a><ul><li><a href=\"#H8525449\" id=\"outline-link-H8525449\">Adjuvant setting</a><ul><li><a href=\"#H8525474\" id=\"outline-link-H8525474\">- Adjuvant gemcitabine</a></li><li><a href=\"#H3643984002\" id=\"outline-link-H3643984002\">- Adjuvant gemcitabine plus capecitabine</a></li></ul></li><li><a href=\"#H8525513\" id=\"outline-link-H8525513\">Locally advanced/metastatic disease</a><ul><li><a href=\"#H8525538\" id=\"outline-link-H8525538\">- Gemcitabine monotherapy</a></li><li><a href=\"#H428485721\" id=\"outline-link-H428485721\">- Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)</a></li><li><a href=\"#H3139598706\" id=\"outline-link-H3139598706\">- Gemcitabine plus capecitabine</a></li><li><a href=\"#H8525617\" id=\"outline-link-H8525617\">- FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)</a></li><li><a href=\"#H2117393642\" id=\"outline-link-H2117393642\">- Modified FOLFIRINOX for metastatic pancreatic cancer</a></li><li><a href=\"#H936511973\" id=\"outline-link-H936511973\">- Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</a></li><li><a href=\"#H2763016320\" id=\"outline-link-H2763016320\">- Liposomal irinotecan and 5-FU for metastatic pancreatic cancer</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85690|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/81436\" class=\"graphic graphic_table\">- Gemcitabine for nonmetastatic pancreatic and biliary cancer</a></li><li><a href=\"image.htm?imageKey=ONC/109104\" class=\"graphic graphic_table\">- GemCap for adjuvant therapy of pancreatic cancer</a></li><li><a href=\"image.htm?imageKey=ONC/60330\" class=\"graphic graphic_table\">- Gemcitabine for metastatic pancreatic and biliary tract cancer</a></li><li><a href=\"image.htm?imageKey=ONC/89668\" class=\"graphic graphic_table\">- Gem plus nabpaclitaxel</a></li><li><a href=\"image.htm?imageKey=ONC/103038\" class=\"graphic graphic_table\">- GemCap for advanced pancreatobiliary cancer</a></li><li><a href=\"image.htm?imageKey=ONC/79571\" class=\"graphic graphic_table\">- FOLFIRINOX for metastatic pancreatic cancer</a></li><li><a href=\"image.htm?imageKey=ONC/109546\" class=\"graphic graphic_table\">- Modified FOLFIRINOX for metastatic pancreatic cancer</a></li><li><a href=\"image.htm?imageKey=ONC/50132\" class=\"graphic graphic_table\">- Modified FOLFOX6</a></li><li><a href=\"image.htm?imageKey=ONC/109026\" class=\"graphic graphic_table\">- Liposomal irinotecan and 5-FU for metastatic pancreatic cancer</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-for-advanced-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Chemotherapy for advanced exocrine pancreatic cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-chemotherapy-and-radiation-for-nonmetastatic-locally-advanced-unresectable-and-borderline-resectable-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Initial chemotherapy and radiation for nonmetastatic, locally advanced, unresectable and borderline resectable, exocrine pancreatic cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-for-potentially-resectable-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Treatment for potentially resectable exocrine pancreatic cancer</a></li></ul></div></div>","javascript":null}